Factor XI/XIa inhibitors: a potential solution to anticoagulation dilemmas

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Hematology

Background:

• Standard antithrombotic therapies for stroke prevention face limitations including underutilization, bleeding risks, drug interactions, and renal elimination.
• Factor XI/XIa (FXI/XIa) inhibitors represent a novel class of anticoagulants designed to selectively target thrombosis, potentially mitigating bleeding complications while preserving efficacy.

Purpose of the Study:

• To review the mechanistic rationale behind FXI/XIa inhibitors.
• To describe different subclasses of FXI/XIa inhibitor molecules.
• To examine barriers to current anticoagulation use and review clinical trial data for FXI/XIa inhibitors.

Main Methods:

• Literature review of mechanistic studies.
• Analysis of existing clinical trial data for FXI/XIa inhibitors.
• Comparison of FXI/XIa inhibitors with current anticoagulation strategies like DOACs.

Main Results:

• FXI/XIa inhibitors show potential advantages over DOACs, including reduced bleeding, fewer drug interactions, and less renal elimination.
• Clinical trials are ongoing to confirm non-inferior efficacy and improved safety profiles compared to DOACs.
• Potential barriers to widespread adoption include cost, lack of specific antidotes, and general underutilization of anticoagulants.

Conclusions:

• FXI/XIa inhibitors hold significant promise for improving stroke prevention strategies.
• Demonstrating non-inferior efficacy and superior safety in clinical trials is crucial for their adoption.
• The development of small molecules and monoclonal antibodies targeting FXI/XIa is advancing rapidly, suggesting a high likelihood of clinical translation.